The modification in the activity of noradrenergic neurons projecting to the hypothalamus and the pituitary-adrenal response during morphine withdrawal as well its correlation with alterations in corticotropin-releasing factor (CRF) and vasopressin (AVP) content in different brain areas was analyzed. Male rats were implanted with placebo (naïve) or morphine (tolerant/dependent) pellets for 7 days. On day 8, groups of rats received an acute injection of saline s.
View Article and Find Full Text PDFIn this study the modification in the oxytocin content in different hypothalamic nuclei during morphine withdrawal was analysed. Male rats were implanted with placebo (naïve) or morphine (tolerant/dependent) pellets for 7 days. On day 7, groups of rats received an acute injection of saline s.
View Article and Find Full Text PDFThe changes in the content of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) in discrete brain nuclei during chronic opioids administration have not been well established. We evaluated the effects of acute and chronic morphine administration on the content of CRF and AVP in different hypothalamic and extrahypothalamic (bed nucleus of the stria terminalis, BNST) nuclei in rats. Concomitantly, changes in hypothalamic noradrenaline (NA) turnover [estimated by the 3-methoxy-4-hydroxyphenylethyleneglycol MHPG/NA ratio] and in plasma corticosterone release (as a marker of the activity of the hypothalamus-pituitary-adrenal axis) were determined.
View Article and Find Full Text PDFThe role of hypothalamic oxytocin neurons in the hypothalamus-pituitary-adrenal (HPA) axis adaptation during opioid tolerance has not been explored. In this study the modification of oxytocin levels in different hypothalamic nuclei was determined after acute or chronic morphine exposure. Male rats were implanted with placebo (naïve) or morphine (tolerant) pellets for 7 days.
View Article and Find Full Text PDFA monoclonal antibody (MAb) to vasopressin (AVP) inhibits the synthesis and the release of AVP when injected near the AVP-producing neurons. In the present experiments, the AVP-MAb was microinjected near the paraventricular (PVN) or the supraoptic (SON) neurons of the rat hypothalamus and the AVP expression was measured in the suprachiasmatic nuclei (SCN). When microinjected near PVN, the AVP-MAb modified the AVP mRNA studied by in situ hybridization, and the AVP immunoreactive content of SCN, whereas it failed to show some effect when injected near SON.
View Article and Find Full Text PDF